Ankylosing Spondylitis with Peripheral Arthritis When Initial Biologic or Targeted Therapy Has Not Achieved Adequate Response
This protocol covers a specific situation: ankylosing spondylitis in a patient with peripheral arthritis as a prominent feature, where the initial biologic or targeted synthetic DMARD has not produced sufficient disease control — and a structured next step is needed.
Clinical Presentation
Peripheral arthritis is the defining feature of this scenario. In patients with predominantly peripheral manifestations, conventional synthetic therapy including sulfasalazine may be considered as part of the prior treatment sequence; failure criteria include one glucocorticoid injection, if appropriate, and a sulfasalazine trial before escalation to a biologic.
Previous Treatment — Failure Condition
The initial biologic regimen — a TNFi or IL-17A inhibitor, or a Janus kinase inhibitor where considered — did not achieve ASDAS clinically important improvement (decrease ≥1.1) after at least 12 weeks. Non-achievement of this target, confirmed by clinical evaluation, is the trigger for escalation to this next-line protocol.
Next-Step Approach & Treatment Goal
The protocol at this stage involves switching to a different class of biologic or targeted synthetic therapy — the full structured regimen specifies which options apply and in what sequence. The treatment target remains ASDAS clinically important improvement (decrease ≥1.1), reassessed after at least 12 weeks, with a positive rheumatologist evaluation required to support continuation.
References
DOI: 10.1136/ard-2022-223296
- Patients with purely axial disease should normally not be treated with csDMARDs; sulfasalazine may be considered in patients with peripheral arthritis.
- In patients with predominantly peripheral manifestations, following recommendations 7 and 8, failure to treatment includes one glucocorticoid injection, if appropriate, and the use of sulfasalazine.
- Following a first b/tsDMARD failure, switching to another bDMARD (TNFi or IL-17i) or a JAKi should be considered.
- Absence of response to treatment should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities.
- Figure 3 summarises the criteria for continuation, namely that after at least 12 weeks of treatment, the disease activity has substantially decreased, as assessed by the ASDAS clinical important improvement, that is, improvement in ASDAS ≥1.1, together with the positive opinion from the rheumatologist to continue.
View source ↗